Who we are
Vibalogics is a global contract development and manufacturing organization (CDMO) offering process and analytical development, manufacturing, testing, and fill-finish services to innovators developing revolutionary virotherapy products.
LEADING THE VIROTHERAPY CDMO MARKET
Experience a unique understanding of virotherapy
We are an ambitious partner with a vision of leading the virotherapy CDMO market by pioneering efficient, economically viable, and GMP compliant manufacture of complex oncolytic viruses, viral vector gene therapies and vaccines, by enabling our customers to deliver transformational products to patients worldwide.
Our industry-leading viral expertise supports your successful progress along the way and helps mitigate challenges frequently seen in this emerging segment of industry, and our comprehensive services support both clinical- and commercial-capability from initial technical transfer, GMP drug substance and drug product manufacture, to quality control batch release facilitating overall speed and security of our customers product supply chain.
Partner with us and you will experience a transparent and consultative partnership. Our ethos of flexibility and open communication provides our customers with the resourceful and adaptable strategies they need to ensure projects are completed successfully, on budget and on time.
Quality infrastructure, continuous investment
Following an impressive track record in virotherapy manufacturing, in April 2022, Vibalogics was acquired by Recipharm AB, a leading Global CDMO. The acquisition of Vibalogics will expand Recipharm’s global business offering along with the company’s additional acquisitions which include GenIbet Biopharmaceuticals S.A. (Oeiras, Portugal) and Arranta Bio (Watertown, MA). Together, the companies will extend their services to the ATMP (advanced therapy medicinal products) market, through a robust end-to-end offering with capabilities spanning development, GMP drug substance and drug product manufacture, sterile fill & finish, and analytical and quality control testing.
Investment and continued re-investment annually into our business has played an important part in our growth strategy including:
Construction of the Boxborough, MA Headquarters for Phase I-III and marketed commercial virotherapy manufacturing services
Expansion of our Cuxhaven, Germany for added capacity for Phase I-II clinical virotherapy manufacturing services
